Cargando…
Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies
Hepatocellular carcinoma is the fourth leading cause of cancer-related death worldwide. Depending on the extent of disease and competing comorbidities for mortality, multiple liver-directed therapy options exist for the treatment of hepatocellular carcinoma. Advancements in radiation oncology have l...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071169/ https://www.ncbi.nlm.nih.gov/pubmed/30068240 http://dx.doi.org/10.1177/1533033818790217 |
_version_ | 1783343823324184576 |
---|---|
author | Schaub, Stephanie K. Hartvigson, Pehr E. Lock, Michael I. Høyer, Morten Brunner, Thomas B. Cardenes, Higinia R. Dawson, Laura A. Kim, Edward Y. Mayr, Nina A. Lo, Simon S. Apisarnthanarax, Smith |
author_facet | Schaub, Stephanie K. Hartvigson, Pehr E. Lock, Michael I. Høyer, Morten Brunner, Thomas B. Cardenes, Higinia R. Dawson, Laura A. Kim, Edward Y. Mayr, Nina A. Lo, Simon S. Apisarnthanarax, Smith |
author_sort | Schaub, Stephanie K. |
collection | PubMed |
description | Hepatocellular carcinoma is the fourth leading cause of cancer-related death worldwide. Depending on the extent of disease and competing comorbidities for mortality, multiple liver-directed therapy options exist for the treatment of hepatocellular carcinoma. Advancements in radiation oncology have led to the emergence of stereotactic body radiation therapy as a promising liver-directed therapy, which delivers high doses of radiation with a steep dose gradient to maximize local tumor control and minimize radiation-induced treatment toxicity. In this study, we review the current clinical data as well as the unresolved issues and controversies regarding stereotactic body radiation therapy for hepatocellular carcinoma: (1) Is there a radiation dose–response relationship with hepatocellular carcinoma? (2) What are the optimal dosimetric predictors of radiation-induced liver disease, and do they differ for patients with varying liver function? (3) How do we assess treatment response on imaging? (4) How does stereotactic body radiation therapy compare to other liver-directed therapy modalities, including proton beam therapy? Based on the current literature discussed, this review highlights future possible research and clinical directions. |
format | Online Article Text |
id | pubmed-6071169 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-60711692018-08-06 Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies Schaub, Stephanie K. Hartvigson, Pehr E. Lock, Michael I. Høyer, Morten Brunner, Thomas B. Cardenes, Higinia R. Dawson, Laura A. Kim, Edward Y. Mayr, Nina A. Lo, Simon S. Apisarnthanarax, Smith Technol Cancer Res Treat Review Hepatocellular carcinoma is the fourth leading cause of cancer-related death worldwide. Depending on the extent of disease and competing comorbidities for mortality, multiple liver-directed therapy options exist for the treatment of hepatocellular carcinoma. Advancements in radiation oncology have led to the emergence of stereotactic body radiation therapy as a promising liver-directed therapy, which delivers high doses of radiation with a steep dose gradient to maximize local tumor control and minimize radiation-induced treatment toxicity. In this study, we review the current clinical data as well as the unresolved issues and controversies regarding stereotactic body radiation therapy for hepatocellular carcinoma: (1) Is there a radiation dose–response relationship with hepatocellular carcinoma? (2) What are the optimal dosimetric predictors of radiation-induced liver disease, and do they differ for patients with varying liver function? (3) How do we assess treatment response on imaging? (4) How does stereotactic body radiation therapy compare to other liver-directed therapy modalities, including proton beam therapy? Based on the current literature discussed, this review highlights future possible research and clinical directions. SAGE Publications 2018-08-01 /pmc/articles/PMC6071169/ /pubmed/30068240 http://dx.doi.org/10.1177/1533033818790217 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Schaub, Stephanie K. Hartvigson, Pehr E. Lock, Michael I. Høyer, Morten Brunner, Thomas B. Cardenes, Higinia R. Dawson, Laura A. Kim, Edward Y. Mayr, Nina A. Lo, Simon S. Apisarnthanarax, Smith Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies |
title | Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current
Trends and Controversies |
title_full | Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current
Trends and Controversies |
title_fullStr | Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current
Trends and Controversies |
title_full_unstemmed | Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current
Trends and Controversies |
title_short | Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current
Trends and Controversies |
title_sort | stereotactic body radiation therapy for hepatocellular carcinoma: current
trends and controversies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071169/ https://www.ncbi.nlm.nih.gov/pubmed/30068240 http://dx.doi.org/10.1177/1533033818790217 |
work_keys_str_mv | AT schaubstephaniek stereotacticbodyradiationtherapyforhepatocellularcarcinomacurrenttrendsandcontroversies AT hartvigsonpehre stereotacticbodyradiationtherapyforhepatocellularcarcinomacurrenttrendsandcontroversies AT lockmichaeli stereotacticbodyradiationtherapyforhepatocellularcarcinomacurrenttrendsandcontroversies AT høyermorten stereotacticbodyradiationtherapyforhepatocellularcarcinomacurrenttrendsandcontroversies AT brunnerthomasb stereotacticbodyradiationtherapyforhepatocellularcarcinomacurrenttrendsandcontroversies AT cardeneshiginiar stereotacticbodyradiationtherapyforhepatocellularcarcinomacurrenttrendsandcontroversies AT dawsonlauraa stereotacticbodyradiationtherapyforhepatocellularcarcinomacurrenttrendsandcontroversies AT kimedwardy stereotacticbodyradiationtherapyforhepatocellularcarcinomacurrenttrendsandcontroversies AT mayrninaa stereotacticbodyradiationtherapyforhepatocellularcarcinomacurrenttrendsandcontroversies AT losimons stereotacticbodyradiationtherapyforhepatocellularcarcinomacurrenttrendsandcontroversies AT apisarnthanaraxsmith stereotacticbodyradiationtherapyforhepatocellularcarcinomacurrenttrendsandcontroversies |